Celecoxib for Breast Cancer | ASCO/COA: Oncology Medical Home | mRNA for Cancer ResearchJuly 19, 2021 | Oncology Internal Medicine Effect of Celecoxib vs. Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients with Breast Cancer Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer? A report on the Randomized European Celecoxib Trial (REACT), a phase 3, randomized, double-blind study conducted in 160 centers across the UK and Germany testing two years of adjuvant celecoxib vs. placebo among 2,639 patients recruited between 2007 and 2012, with follow-up 10 years after treatment completion. Read full article Hematology Oncology Medical Home: ASCO and COA Standards Oncology Medical Home (OMH) is a system of care delivery that features coordinated, efficient, accessible, and evidence-based care and includes a process for measurement of outcomes to facilitate continuous quality improvement. OMH can serve as a roadmap to guide how a practice delivers high-quality oncology care (a process of practice transformation) and support (but not define) new models of value-based reimbursement. Read full article Hematology mRNA Takes Center Stage in COVID-19 Vaccine and Cancer Research Messenger RNA (mRNA) is in the spotlight right now as the basis of the Moderna and Pfizer/BioNTech vaccines for COVID-19. Thanks to this newfound prominence, its profile has been raised as a powerful tool in cancer research as well. As a courier of genetic information and protein assembler, mRNA can tell scientists which genes are active within a cell and produce the proteins that alert the immune system to the presence of cancer. Read full article
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS